Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Supply increase to help meet growing global demand
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
We now rank 3rd in pharmaceutical production by volume and 14th by value
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
Subscribe To Our Newsletter & Stay Updated
